429 related articles for article (PubMed ID: 25467252)
1. Management of post-transplant Epstein-Barr virus-related lymphoproliferative disease in solid organ and hematopoietic stem cell recipients.
Marques HH; Shikanai-Yasuda MA; dAzevedo LS; Caiaffa-Filho HH; Pierrotti LC; Aquino MZ; Lopes MH; Maluf NZ; Campos SV; Costa SF
Rev Soc Bras Med Trop; 2014; 47(5):543-6. PubMed ID: 25467252
[TBL] [Abstract][Full Text] [Related]
2. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
San-Juan R; Comoli P; Caillard S; Moulin B; Hirsch HH; Meylan P;
Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():109-18. PubMed ID: 24475976
[TBL] [Abstract][Full Text] [Related]
4. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
Styczynski J; Einsele H; Gil L; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
[TBL] [Abstract][Full Text] [Related]
5. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients.
Wareham NE; Mocroft A; Sengeløv H; Da Cunha-Bang C; Gustafsson F; Heilmann C; Iversen M; Kirkby NS; Rasmussen A; Sørensen SS; Lundgren JD;
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1569-1580. PubMed ID: 29804164
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.
Overkamp M; Granai M; Bonzheim I; Steinhilber J; Schittenhelm J; Bethge W; Quintanilla-Martinez L; Fend F; Federmann B
Virchows Arch; 2021 Jun; 478(6):1135-1148. PubMed ID: 33324999
[TBL] [Abstract][Full Text] [Related]
7. Management of post-transplant lymphoproliferative disorders.
Llaurador G; McLaughlin L; Wistinghausen B
Curr Opin Pediatr; 2017 Feb; 29(1):34-40. PubMed ID: 27906865
[TBL] [Abstract][Full Text] [Related]
8. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
San-Juan R; Manuel O; Hirsch HH; Fernández-Ruiz M; López-Medrano F; Comoli P; Caillard S; Grossi P; Aguado JM; ;
Clin Microbiol Infect; 2015 Jun; 21(6):604.e1-9. PubMed ID: 25686696
[TBL] [Abstract][Full Text] [Related]
9. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients.
Green M; Michaels MG; Webber SA; Rowe D; Reyes J
Pediatr Transplant; 1999 Nov; 3(4):271-81. PubMed ID: 10562971
[TBL] [Abstract][Full Text] [Related]
10. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia.
Weintraub L; Weiner C; Miloh T; Tomaino J; Joashi U; Benchimol C; Strauchen J; Roth M; Wistinghausen B
J Pediatr Hematol Oncol; 2014 Nov; 36(8):e481-6. PubMed ID: 24878618
[TBL] [Abstract][Full Text] [Related]
11. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
Romero S; Montoro J; Guinot M; Almenar L; Andreu R; Balaguer A; Beneyto I; Espí J; Gómez-Codina J; Iacoboni G; Jarque I; López-Andújar R; Mayordomo-Aranda E; Montalar J; Pastor A; Pastor M; Piñana JL; Rojas-Ferrer N; Sánchez-Lázaro I; Sandoval J; Sanz G; Sanz MÁ; Solé A; Sanz J
Leuk Lymphoma; 2019 Jan; 60(1):142-150. PubMed ID: 29966464
[TBL] [Abstract][Full Text] [Related]
13. [Prophylaxis against Epstein Barr disease in pediatric and adult patients undergoing solid organ and hematopoietic stem cells transplantation].
Catalán P; Alba A
Rev Chilena Infectol; 2012 Sep; 29 Suppl 1():S29-31. PubMed ID: 23282553
[TBL] [Abstract][Full Text] [Related]
14. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
Kogan-Liberman D; Burroughs M; Emre S; Moscona A; Shneider BL
J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
[TBL] [Abstract][Full Text] [Related]
15. Who is the patient at risk for EBV reactivation and disease: expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation.
Marjanska A; Styczynski J
Expert Opin Biol Ther; 2023; 23(6):539-552. PubMed ID: 36971380
[TBL] [Abstract][Full Text] [Related]
16. A Focused Review of Epstein-Barr Virus Infections and PTLD in Pediatric Transplant Recipients: Guidance From the IPTA and ECIL Guidelines.
Yamada M; L'Huillier AG; Green M
J Pediatric Infect Dis Soc; 2024 Feb; 13(Supplement_1):S31-S38. PubMed ID: 38417085
[TBL] [Abstract][Full Text] [Related]
17. [Latest update on immunotherapy of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease].
Hao QF; Sheng GY; Luan Z
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Sep; 15(9):795-9. PubMed ID: 24034931
[TBL] [Abstract][Full Text] [Related]
18. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
Peters AC; Akinwumi MS; Cervera C; Mabilangan C; Ghosh S; Lai R; Iafolla M; Doucette K; Preiksaitis JK
Transplantation; 2018 Sep; 102(9):1553-1562. PubMed ID: 29485513
[TBL] [Abstract][Full Text] [Related]
19. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
Martinez OM; Krams SM
Transplantation; 2017 Sep; 101(9):2009-2016. PubMed ID: 28376031
[TBL] [Abstract][Full Text] [Related]
20. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
